Clinical Medicine Reviews in Therapeutics 2011:3 325-346
Review
Published on 19 Sep 2011
DOI: 10.4137/CMRT.S7398
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Pregabalin is an alpha2-gamma ligand indicated for the treatment of peripheral and central neuropathic pain. In this article, we will review the pharmacodynamics, pharmacokinetics, randomized clinical trials supporting its efficacy for a wide array of neuropathic painful conditions, and the tolerability of this medication. We will comment the main differences with gabapentin, its parent compound, both from the pharmacological and clinical perspective. Our experience in the clinical practice setting with pregabalin, its use in patients with refractory neuropathic pain and its rational use in combination regimens will also be reviewed. With all this information in mind, the place of pregabalin in the pharmacotherapy of neuropathic pain is explored, mainly through the review of recent clinical guidelines which, in fact, place pregabalin among the first-line treatments for the management of most neuropathic painful conditions.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
The submission process was made very simple and easy, and I found the journal's staff to be very receptive and helpful. The online process was very user-friendly. I hope to work with this journal again in the future.
Facebook Google+ Twitter
Pinterest Tumblr YouTube